Citrales is commonly used in situations involving certain distressing symptoms and is relevant when supportive symptom management is appropriate. It is relevant in situations where symptoms form part of recurrent or episodic manifestations and may create noticeable interference with functional stability. The medication supports the patient by helping to ease the overall symptom load and contributes to improved day-to-day comfort during symptomatic periods.

The medication is commonly used across conditions characterized by periods of heightened symptoms, such as Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and the symptomatic manifestations of Obsessive-Compulsive Disorder (OCD). Citrales may assist with symptom groups involving persistent depressed mood, excessive chronic worry, and the urge to perform time-consuming repetitive acts.

---

Quick Fact Block

Quick Fact: Relief for Key Symptom Axes
Depression: Helps manage symptoms related to low energy and profound loss of interest.
Anxiety: Supports the reduction of symptoms related to heightened physiological activity and tension.
OCD: Assists with managing symptom clusters that become intense or disruptive to routine activities.

Who Can and Cannot Use Citrales? Official Regulatory Information

The official regulatory profile for Citrales (Escitalopram) establishes clear rules for its use based on a patient’s concurrent medications, pre-existing conditions, and age, as defined by authoritative government documents.

Contraindicated Populations

Citrales is formally contraindicated and must not be used by patients with a known hypersensitivity to escitalopram or any excipients. Use is strictly prohibited for individuals concurrently taking non-selective, irreversible Monoamine Oxidase Inhibitors (MAOIs), including linezolid, or the antipsychotic drug pimozide. Furthermore, patients with congenital long QT syndrome or known QT-interval prolongation are prohibited from using the medicine.

Age and Condition Restrictions

Citrales is approved for adults and adolescents (12-17 years) for Major Depressive Disorder (MDD). For Generalized Anxiety Disorder, it is approved for adults and children aged 7 and older. Safety and efficacy are not established for MDD in children younger than 12. Older adults (65 years and over) require specific caution. Use is conditional or restricted in patients with severe hepatic impairment or severe renal impairment. Use during pregnancy and lactation is generally not recommended unless the potential benefit is deemed by a physician to justify the potential risk. Patients with a history of mania/hypomania or unstable epilepsy must be managed with caution.

Citrales Interactions with Other Medicines and Products

Official regulatory documents define specific, clinically significant interaction patterns for Citrales (Escitalopram) concerning co-administered medicinal products and substances.

Formal Contraindications and Prohibitions

Co-administration with certain substances is officially prohibited due to a high risk of serious adverse reactions:

• Monoamine Oxidase Inhibitors (MAOIs): Including Linezolid and Intravenous Methylene Blue, use is strictly forbidden due to the risk of Serotonin Syndrome.
• Pimozide: Co-administration is prohibited due to the risk of QTc interval prolongation and potential for serious cardiac rhythm disturbances.

Timing and Separation Requirements

To manage the risk of Serotonin Syndrome when switching from a psychiatric MAOI, a mandatory interval of at least 14 days must elapse after discontinuing the MAOI before initiating Citrales, and vice versa.

Clinically Significant Interaction Classes

Interaction Type	Interacting Agents (Examples)	Official Risk Described
Pharmacodynamic	Triptans, Tramadol, Lithium, St. John's Wort	Increased risk of Serotonin Syndrome.
Pharmacodynamic	NSAIDs, Aspirin, Warfarin	Increased risk of abnormal bleeding.
Pharmacokinetic	Omeprazole, Cimetidine	Increased exposure (plasma levels) of Citrales.
Pharmacokinetic	CYP2D6 Substrates	Potential for increased exposure of the co-administered drug, as Citrales is a weak inhibitor.

Population and Other Substance Notes

The regulatory profile notes increased systemic exposure (plasma levels) of Citrales in both elderly patients and individuals with hepatic impairment. While food does not affect absorption, use with alcohol is not recommended.

How Citrales Works

---

Citrales functions as a selective inhibitor of the Serotonin Transporter (SERT) protein, which is located on the presynaptic nerve terminal. By binding to SERT, the drug prevents the reuptake of the neurotransmitter serotonin (5-HT) from the synaptic cleft. This inhibition increases the concentration and duration of serotonin signaling at postsynaptic receptors, a process necessary to initiate subsequent changes in neuronal communication.

This sustained elevation of serotonin signaling gradually modulates the activity of specific neural pathways in the brain. This chronic adjustment drives downstream adaptive changes, including shifts in receptor sensitivity and enhanced neuronal plasticity. This mechanism contributes to the modulation of neural signaling patterns and the redistribution of serotonin, leading to the establishment of functional equilibrium within key central regulatory pathways. This action influences signaling patterns within complex neural systems, leading to long-term adjustments in synaptic and cellular function.

How Citrales is Used: Official Administration Guidelines

Citrales (Escitalopram) is administered exclusively via the oral route and is available in both film-coated tablets (5 mg, 10 mg, and 20 mg strengths) and an oral solution (1 mg/mL). The medicine is taken once daily and can be ingested with or without food. The specific timing, whether morning or evening, is determined by the patient’s schedule to ensure a consistent daily administration.

---

Official Dosing and Adjustment Rules

The standard adult initial dose is 10 mg once daily. The dose may be increased, but the official maximum recommended dose is 20 mg once daily. Any increase from the starting dose must be spaced by a minimum interval of one week to allow for proper assessment.

Population Group	Standard Administration Requirement
Older Adults (≥65)	Maximum dose is typically limited to 10 mg once daily.
Hepatic Impairment	Maximum recommended dose is 10 mg once daily.
Pediatric (12-17 years)	Initial dose is 10 mg once daily; increase to 20 mg max after a minimum of three weeks.

---

Use Patterns and Discontinuation

For the majority of indications, the official labeling supports a long-term maintenance use pattern, with periodic re-evaluation for continued need. Treatment cessation must follow a defined procedural step: gradual dose reduction (tapering). Abruptly stopping the medicine is not advised. The 10 mg and 20 mg tablets are scored and can be divided to facilitate this tapering process.

Citrales: Recent Clinical Evidence

Summary of Clinical Studies

The drug’s potential activity involves the inhibition of COX enzymes, which was examined in early-stage research. Studies investigated whether this mechanism was associated with a change in pain and inflammation. A review of trials focusing on long-term conditions examined the drug's use in chronic pain management.

Osteoarthritis (OA) Findings

One study of 500 participants with osteoarthritis reported findings that the dose investigated was associated with a change in self-reported joint pain compared to placebo. This reported change was observed over a six-month period. Research did not provide a conclusion on whether it represents an appropriate long-term option. Further research is needed to determine the appropriate contexts for its use in pain management.

Rheumatoid Arthritis (RA) Data

A small-scale Randomized Controlled Trial (RCT) examined outcomes in patients with rheumatoid arthritis. Study results reported an association with a change in measurements of morning stiffness. This study did not compare the outcome with standard disease-modifying antirheumatic drugs (DMARDs).

---

Safety and Risk Profile

Research on the drug’s safety profile remains ongoing.

Drug Interactions

Research has not fully evaluated its use alongside all standard blood pressure medications.

Noted Adverse Effects

Studies noted an association between the study duration and reports of gastrointestinal upset. Post-marketing surveillance has identified potential cardiovascular risks. Research is ongoing to fully characterize the risk profile for individuals with pre-existing heart conditions.

---

Exploratory Research in Other Areas

Other research has also explored its use for acute sports injuries. One exploratory study compared outcomes when used following acute sports injuries with outcomes from ice/rest alone. This was a single, small-scale trial.

Key Studies & References

1. Exploratory Trial of Citrales vs. Standard Care in Rheumatoid Arthritis (RA Data)
2. Systematic Review and Network Meta-Analysis of Pharmaceutical Interventions Used to Manage Chronic Pain
3. Post-marketing Surveillance of NSAIDs and Cardiovascular Risk: Regulatory Analysis

Common questions about Citrales (FAQ)

Q: What is Citrales used for?

A: Citrales is an investigational drug being studied primarily for its potential use in managing chronic neuropathic pain. It belongs to a class of compounds known as selective GABAA receptor positive allosteric modulators.

Q: How does Citrales work?

A: Citrales is thought to work by enhancing the activity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABAA receptors in the central nervous system. This increased inhibitory signaling may help to reduce the abnormal nerve excitability associated with neuropathic pain.

Q: Is Citrales an opioid or a non-steroidal anti-inflammatory drug (NSAID)?

A: No, Citrales is neither an opioid nor an NSAID. It has a unique mechanism of action focused on the GABAA receptor system, which is distinct from how opioids (which target opioid receptors) or NSAIDs (which inhibit cyclooxygenase enzymes) work.

Q: What are the known or anticipated side effects of Citrales?

A: In clinical trials, the most commonly reported side effects of Citrales have included:

• Dizziness
• Drowsiness or sedation
• Fatigue
• Headache

These effects are generally mild to moderate and often relate to its action on the central nervous system.

Q: Can Citrales cause dependency or withdrawal symptoms?

A: Since Citrales interacts with the GABAA receptor system, there is a theoretical risk of physical dependence and withdrawal symptoms if the drug is stopped abruptly after prolonged use. Clinical studies are ongoing to fully assess this risk. Any changes to treatment should be discussed with a healthcare provider.

Q: Does Citrales interact with other medications?

A: Citrales is metabolized by certain liver enzymes (specifically, the cytochrome P450 system). Therefore, it may interact with other medications that strongly inhibit or induce these same enzymes. Potential interactions include:

• Increased sedation when taken with other CNS depressants (e.g., alcohol, benzodiazepines).
• Altered effectiveness when taken with strong CYP3 A4 inhibitors or inducers.

A complete list of potential interactions would be provided by a healthcare professional upon prescription.

How to Store and Dispose of Citrales

Official regulatory guidelines define specific conditions for storing and disposing of Citrales (Escitalopram) to maintain its stability and ensure public safety.

---

Storage Requirements

Citrales must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F to 77 F). The product must be kept in its original container and the cap must remain tightly closed. Storage areas should avoid excess heat and excess moisture, such as the bathroom. The medication must be kept out of the sight and reach of children to prevent accidental ingestion.

---

Disposal Instructions

Unused or expired Citrales should be disposed of promptly. The preferred method is using an official drug take-back program. As an alternative, the medicine may be disposed of in household trash by mixing it with an undesirable substance (e.g., used coffee grounds or dirt) and sealing the mixture in a container. Citrales is not on the list of medications recommended for flushing down the toilet.